DE602004020734D1 - Derivate von piperazine-2-carboxamide - Google Patents
Derivate von piperazine-2-carboxamideInfo
- Publication number
- DE602004020734D1 DE602004020734D1 DE602004020734T DE602004020734T DE602004020734D1 DE 602004020734 D1 DE602004020734 D1 DE 602004020734D1 DE 602004020734 T DE602004020734 T DE 602004020734T DE 602004020734 T DE602004020734 T DE 602004020734T DE 602004020734 D1 DE602004020734 D1 DE 602004020734D1
- Authority
- DE
- Germany
- Prior art keywords
- piperazine
- carboxamide
- derivatives
- labor
- dysmenorrhea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- BRYCUMKDWMEGMK-UHFFFAOYSA-N piperazine-2-carboxamide Chemical class NC(=O)C1CNCCN1 BRYCUMKDWMEGMK-UHFFFAOYSA-N 0.000 title abstract 2
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 208000005107 Premature Birth Diseases 0.000 abstract 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 abstract 1
- 206010036590 Premature baby Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03003422 | 2003-02-14 | ||
PCT/EP2004/050093 WO2004071390A2 (en) | 2003-02-14 | 2004-02-06 | Piperazine-2-carboxamide derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004020734D1 true DE602004020734D1 (de) | 2009-06-04 |
Family
ID=32864935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004020734T Expired - Lifetime DE602004020734D1 (de) | 2003-02-14 | 2004-02-06 | Derivate von piperazine-2-carboxamide |
Country Status (10)
Country | Link |
---|---|
US (1) | US8404690B2 (de) |
EP (1) | EP1592389B1 (de) |
JP (1) | JP4825664B2 (de) |
AT (1) | ATE429228T1 (de) |
AU (1) | AU2004212335A1 (de) |
CA (1) | CA2513716A1 (de) |
DE (1) | DE602004020734D1 (de) |
ES (1) | ES2324535T3 (de) |
NO (1) | NO20053991L (de) |
WO (1) | WO2004071390A2 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1511488B1 (de) | 2002-06-12 | 2013-05-22 | Symphony Evolution, Inc. | Humane adam-10-hemmer |
US7754722B2 (en) * | 2002-09-20 | 2010-07-13 | Merck Serono Sa | Piperazine derivatives and methods of use |
PT1558582E (pt) | 2003-07-22 | 2006-05-31 | Arena Pharm Inc | Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
EP2044038B1 (de) * | 2006-06-06 | 2014-07-02 | Cornerstone Therapeutics Inc. | Neue piperazine, pharmazeutische zusammensetzungen und anwendungsverfahren dafür |
SG175609A1 (en) | 2006-10-09 | 2011-11-28 | Takeda Pharmaceutical | Kinase inhibitors |
EP2254564A1 (de) | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
JP6902466B2 (ja) * | 2014-11-07 | 2021-07-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ミオカルディン関連転写因子および血清応答因子(mrtf/srf)媒介性遺伝子転写の阻害剤ならびにその使用方法 |
RU2017145976A (ru) | 2015-06-12 | 2019-07-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна |
KR20180064373A (ko) | 2015-07-15 | 2018-06-14 | 엑소반트 사이언시즈 게엠베하 | 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체 |
WO2019104011A1 (en) * | 2017-11-21 | 2019-05-31 | Biomarin Pharmaceutical Inc. | Ceramide galactosyltransferase inhibitors for the treatment of disease |
WO2020028221A1 (en) * | 2018-07-30 | 2020-02-06 | Biomarin Pharmaceutical Inc. | Ceramide galactosyltransferase inhibitors for the treatment of disease |
WO2021037699A1 (en) * | 2019-08-26 | 2021-03-04 | Société des Produits Nestlé S.A. | Myo-inositol and the prevention of preterm birth |
WO2021037698A1 (en) * | 2019-08-26 | 2021-03-04 | Société des Produits Nestlé S.A. | Myo-inositol and the prevention of pprom |
WO2023215205A1 (en) * | 2022-05-06 | 2023-11-09 | Merck Sharp & Dohme Llc | Orexin receptor agonists |
WO2024107615A1 (en) * | 2022-11-17 | 2024-05-23 | Merck Sharp & Dohme Llc | Orexin receptor agonists |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6450818A (en) | 1987-08-20 | 1989-02-27 | Tsumura & Co | Prostaglandin f2alpha-inhibitor |
US6271201B1 (en) * | 1993-07-15 | 2001-08-07 | Board Of Regents, The University Of Texas System | Methods for the selective regulation of placental prostanoids and inhibition of labor using IGF-I |
TW472047B (en) | 1994-02-04 | 2002-01-11 | Merck & Co Inc | Process for making HIV protease inhibitors |
US5612484A (en) * | 1995-05-18 | 1997-03-18 | Merck & Co., Inc. | Process for making HIV protease inhibitors |
EP1095936B1 (de) * | 1995-12-08 | 2004-11-24 | Agouron Pharmaceuticals, Inc. | Zwischenprodukte zur Herstellung von Metallproteinasehemmern |
DE69926078T2 (de) * | 1998-12-23 | 2006-04-20 | Schering Corp. | Farnesyl-protein transferase inhibitoren |
WO2000077519A1 (en) * | 1999-06-15 | 2000-12-21 | Aventis Pharmaceuticals Products Inc. | Solid phase synthesis of n,n-disubstituted diazacycloalkylcarboxy derivatives |
WO2002026720A2 (en) * | 2000-09-29 | 2002-04-04 | Millennium Pharmaceuticals, Inc. | PIPERAZINE BASED INHIBITORS OF FACTOR Xa |
AU2002248322B2 (en) | 2001-01-24 | 2005-06-09 | The Arizona Board Of Regents, On Behalf Of, The University Of Arizona | Methods for screening for substances which inhibit FP prostanoid receptor interaction with a compound having PGF2alphaalphaactivity and methods of treating cancer |
US7754722B2 (en) | 2002-09-20 | 2010-07-13 | Merck Serono Sa | Piperazine derivatives and methods of use |
-
2004
- 2004-02-06 WO PCT/EP2004/050093 patent/WO2004071390A2/en active Application Filing
- 2004-02-06 US US10/545,296 patent/US8404690B2/en not_active Expired - Fee Related
- 2004-02-06 AU AU2004212335A patent/AU2004212335A1/en not_active Abandoned
- 2004-02-06 ES ES04708776T patent/ES2324535T3/es not_active Expired - Lifetime
- 2004-02-06 CA CA002513716A patent/CA2513716A1/en not_active Abandoned
- 2004-02-06 EP EP04708776A patent/EP1592389B1/de not_active Expired - Lifetime
- 2004-02-06 JP JP2006502009A patent/JP4825664B2/ja not_active Expired - Fee Related
- 2004-02-06 AT AT04708776T patent/ATE429228T1/de not_active IP Right Cessation
- 2004-02-06 DE DE602004020734T patent/DE602004020734D1/de not_active Expired - Lifetime
-
2005
- 2005-08-26 NO NO20053991A patent/NO20053991L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ES2324535T3 (es) | 2009-08-10 |
EP1592389B1 (de) | 2009-04-22 |
NO20053991L (no) | 2005-08-26 |
ATE429228T1 (de) | 2009-05-15 |
JP4825664B2 (ja) | 2011-11-30 |
AU2004212335A1 (en) | 2004-08-26 |
US8404690B2 (en) | 2013-03-26 |
WO2004071390A3 (en) | 2004-12-23 |
CA2513716A1 (en) | 2004-08-26 |
US20070142391A1 (en) | 2007-06-21 |
WO2004071390A2 (en) | 2004-08-26 |
AU2004212335A8 (en) | 2004-08-26 |
JP2006517566A (ja) | 2006-07-27 |
EP1592389A2 (de) | 2005-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20053991L (no) | Piperazin-2-karboksamidderivater | |
MX2007000505A (es) | Derivados de oxindol sustituidos y medicamentos que contienen los mismos. | |
EA201000563A1 (ru) | Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i | |
NO20080963L (no) | Piperidinyl-substiuerte isokinolinderivater som Rho-kinaseinhibitorer | |
DE60204322D1 (de) | Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen | |
EA200401270A1 (ru) | Тиазолидинкарбоксамидные производные как модуляторы рецептора простагландина f | |
CY1113736T1 (el) | Ετεροαρυλ-ουριες και η χρηση τους ως ενεργοποιητες γλυκοκινασης | |
MY135841A (en) | Novel benzodioxoles | |
MY140031A (en) | Carbonyl compounds | |
DE60315146D1 (de) | Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase | |
NO20062020L (no) | 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika | |
MXPA05013536A (es) | Derivados de etinilprolina. | |
NO20080394L (no) | N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav | |
BRPI0519267A2 (pt) | derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo | |
WO2003106450A8 (de) | Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren | |
ATE429916T1 (de) | Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme | |
UA85676C2 (en) | Carbonyl compounds | |
ATE399175T1 (de) | Hemmstoffe der urokinase, ihre herstellung und verwendung | |
DE602005020836D1 (de) | Pyrimidothienindazole als tyrosinkinasehemmer des epidermalen wachstumsfaktors | |
DK1558620T3 (da) | Rutheniumkomplekser med anticancervirkning | |
NO20053876D0 (no) | Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav | |
ATE458482T1 (de) | Verwendung von amino substituierten benzimidazolen | |
DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
ATE371662T1 (de) | Siliziumverbindungen und deren verwendung | |
BRPI0409405A (pt) | compostos 7-aza-quinazolina substituìdos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |